Memphasys (Australia) Today

MEM Stock   0.01  0  14.29%   

Performance

Fair

 
Weak
 
Strong

Odds Of Distress

Strong

 
High
 
Low
Memphasys is selling for under 0.006 as of the 27th of February 2026; that is 14.29 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.006. Memphasys has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 29th of November 2025 and ending today, the 27th of February 2026. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
Category
Healthcare
Classification
Health Care
Memphasys is entity of Australia. It is traded as Stock on AU exchange. The company has 2.85 B outstanding shares. More on Memphasys

Moving together with Memphasys Stock

  0.74MQG Macquarie GroupPairCorr

Moving against Memphasys Stock

  0.68PME Pro MedicusPairCorr
  0.57REA REA GroupPairCorr
  0.52CSL CSLPairCorr
  0.41COH CochlearPairCorr

Memphasys Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Memphasys' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Memphasys or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO MDBE BE
Business ConcentrationLife Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors)
Memphasys' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Memphasys' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Debt Levels
Memphasys can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Memphasys' financial leverage. It provides some insight into what part of Memphasys' total assets is financed by creditors.
Liquidity
Memphasys cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. Memphasys has accumulated 5.11 M in total debt. Debt can assist Memphasys until it has trouble settling it off, either with new capital or with free cash flow. So, Memphasys' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Memphasys sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Memphasys to invest in growth at high rates of return. When we think about Memphasys' use of debt, we should always consider it together with cash and equity.

Total Cashflows From Investing Activities

(636,248)
Memphasys (MEM) is traded on Australian Securities Exchange in Australia and employs 10 people. Memphasys is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.08 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Memphasys's market, we take the total number of its shares issued and multiply it by Memphasys's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Memphasys operates under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 2.85 B outstanding shares. Memphasys generates negative cash flow from operations
Check Memphasys Probability Of Bankruptcy
Ownership Allocation
Memphasys maintains a total of 2.85 Billion outstanding shares. Memphasys holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Memphasys Ownership Details

Memphasys Historical Income Statement

At this time, Memphasys' Interest Expense is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 1.1 M in 2026, whereas Selling And Marketing Expenses is likely to drop slightly above 76.6 K in 2026. View More Fundamentals

Memphasys Stock Against Markets

Memphasys Stock Analysis Notes

About 36.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.67. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Memphasys had not issued any dividends in recent years. The entity had 1:15 split on the 16th of August 2018. To find out more about Memphasys contact BE BE at 61 2 8415 7300 or learn more at https://www.memphasys.com.

Memphasys Investment Alerts

Memphasys is way too risky over 90 days horizon
Memphasys has some characteristics of a very speculative penny stock
Memphasys appears to be risky and price may revert if volatility continues
Memphasys has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 526.92 K. Net Loss for the year was (4.94 M) with profit before overhead, payroll, taxes, and interest of 431.06 K.
Memphasys generates negative cash flow from operations
About 36.0% of the company outstanding shares are owned by corporate insiders

Memphasys Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.08 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Memphasys's market, we take the total number of its shares issued and multiply it by Memphasys's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

Memphasys has return on total asset (ROA) of (0.1779) % which means that it has lost $0.1779 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9832) %, meaning that it generated substantial loss on money invested by shareholders. Memphasys' management efficiency ratios could be used to measure how well Memphasys manages its routine affairs as well as how well it operates its assets and liabilities. Total Current Liabilities is likely to drop to about 3.7 M in 2026. Liabilities And Stockholders Equity is likely to drop to about 11 M in 2026
Leadership effectiveness at Memphasys is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Operating Margin
(7.74)
Beta
0.263
Return On Assets
(0.18)
Return On Equity
(0.98)

Technical Drivers

As of the 27th of February, Memphasys secures the Risk Adjusted Performance of 0.1021, mean deviation of 7.79, and Downside Deviation of 15.71. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Memphasys, as well as the relationship between them.

Memphasys Price Movement Analysis

Transformation
The output start index for this execution was zero with a total number of output elements of sixty-one. Memphasys Tanh Of Price Series is a hyperbolic price transformation function.

Memphasys Outstanding Bonds

Memphasys issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Memphasys uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Memphasys bonds can be classified according to their maturity, which is the date when Memphasys has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Memphasys Predictive Daily Indicators

Memphasys intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Memphasys stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Memphasys Forecast Models

Memphasys' time-series forecasting models are one of many Memphasys' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Memphasys' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Memphasys without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Odds Of Bankruptcy Now

   

Odds Of Bankruptcy

Get analysis of equity chance of financial distress in the next 2 years
All  Next Launch Module

Memphasys Corporate Directors

ScD AitkenScientific DirectorProfile
Pablo NeyertzDirector FinanceProfile
David AliActing DirectorProfile
Associate BakosDirector OperationsProfile

Additional Tools for Memphasys Stock Analysis

When running Memphasys' price analysis, check to measure Memphasys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Memphasys is operating at the current time. Most of Memphasys' value examination focuses on studying past and present price action to predict the probability of Memphasys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Memphasys' price. Additionally, you may evaluate how the addition of Memphasys to your portfolios can decrease your overall portfolio volatility.